Characterizing 16-Week Responder Profiles Using Group-Based Trajectory Modeling in Over 4300 Clinical Trial Participants Receiving Pharmaceutical Treatment for Moderate to Severe Osteoarthritis-论文-万方医学网

首页> > Characterizing 16-Week Responder Profiles Using Group-Based Trajectory Modeling in Over 4300 Clinical Trial Participants Receiving Pharmaceutical Treatment for Moderate to Severe Osteoarthritis

Characterizing 16-Week Responder Profiles Using Group-Based Trajectory Modeling in Over 4300 Clinical Trial Participants Receiving Pharmaceutical Treatment for Moderate to Severe Osteoarthritis

导出原文传递

翻译打印收藏纠错

第一作者： Thomas J.,Schnitzer

作者： Thomas J.,Schnitzer ^[1] ; Gianluca,Bonfanti ^[2] ; Joanna,Atkinson ^[3] ; Sean,Donevan ^[4] ; Lars,Viktrup ^[5] ; Joana,Barroso ^[6] ; Edward,Whalen ; Roger A.,Edwards

作者单位： Department of Physical Medicine and Rehabilitation,Northwestern University Feinberg School of ^[1] Engineering Ingegneria Informatica,SPA ^[2] Pfizer, LTD ^[3] Pfizer Inc. ^[4] Eli Lilly and Company ^[5] Health Services Consulting Corporation ^[6]

关键词 Group-based trajectory modeling Nonsteroidal anti-inflammatory drugs Osteoarthritis Pain Placebo Responder profiles Tanezumab

发布时间 2022-11-01

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览1

相似文献

中文期刊
外文期刊
学位论文
会议论文

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

法律状态公告日	法律状态	法律状态信息

检索历史清除

Characterizing 16-Week Responder Profiles Using Group-Based Trajectory Modeling in Over 4300 Clinical Trial Participants Receiving Pharmaceutical Treatment for Moderate to Severe Osteoarthritis

相似文献

同项目论文

相关期刊

检索历史 清除

Characterizing 16-Week Responder Profiles Using Group-Based Trajectory Modeling in Over 4300 Clinical Trial Participants Receiving Pharmaceutical Treatment for Moderate to Severe Osteoarthritis

相似文献

同项目论文

相关期刊

检索历史清除